Literature DB >> 18813120

False positive labeling of prostate cancer with high molecular weight cytokeratin: p63 a more specific immunomarker for basal cells.

Tehmina Z Ali1, Jonathan I Epstein.   

Abstract

Occasional nonspecific staining of prostate cancer cells with high molecular weight cytokeratin (HMWCK) can lead to false-negative diagnoses. We compared p63 and HMWCK immunostaining to check their specificity for basal cell identification. Out of 6887 prostate cancer cases sent in consultation to one of the authors over 1.5 years, we identified 22 (0.3%) cases with HMWCK labeling of cancer cells, including 20 needle biopsies and 2 transurethral resections of prostate (TURP). Cases were sent in consultation because of the confusing immunostaining pattern, where prostate cancer cells labeled with HMWCK at the outside institutions. In 6 cases, p63 immunostains were also received from the outside institution, whereas in the remaining 16 cases p63 immunohistochemistry was performed at our institution. In 14 cases, we used either an extra destained hematoxylin and eosin slide or a negative control slide for immunohistochemistry with antibodies to p63, and in the 2 remaining cases submitted unstained slides were used. The Gleason scores were 3+3=6 in 20 cases and 4+4=8 in 2 cases. The size of the tumor on needle biopsy ranged from 0.5 to 6.0 mm (mean 1 mm) and on the 2 TURP cases consisted of 44 and 68 cancer glands, respectively. The number of tumor cells positive for HMWCK in each of the needle biopsy cases ranged from 3 to 48 (mean 13 cells), whereas on the 2 TURP cases 26 and 10 cells were labeled with HMWCK. Corresponding stains for p63 on the same cases were negative in 18 cases. In 3 of 4 cases, p63 labeled 1, 1, and 2 tumor cells, respectively. The fourth case had 5 positive cells on p63 staining with 4 positive for HMWCK. To assess whether overstaining was a factor, we evaluated the intensity of HMWCK staining in the basal cells of the benign glands, which was moderate in 6 and strong in 16 cases. The cytoplasm of benign secretory cells showed focal weak (n=3), diffuse weak (n=1), and focal moderate (n=2) staining for HMWCK. HMWCK labeling of prostate cancer cells is uncommon and does not seem to be solely attributable to overstaining. p63 is a more specific marker for basal cells than HMWCK, with less labeling of tumor cells. Recognition of this phenomenon and performing stains for p63 when it occurs can help prevent underdiagnosing prostatic carcinoma.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18813120     DOI: 10.1097/PAS.0b013e31817ce994

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  10 in total

1.  TAp63 and ΔNp63 (p40) in prostate adenocarcinomas: ΔNp63 associates with a basal-like cancer stem cell population but not with metastasis.

Authors:  Michaela Galoczova; Rudolf Nenutil; Zuzana Pokorna; Borivoj Vojtesek; Philip J Coates
Journal:  Virchows Arch       Date:  2020-10-10       Impact factor: 4.064

2.  Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells.

Authors:  Josep Domingo-Domenech; Samuel J Vidal; Veronica Rodriguez-Bravo; Mireia Castillo-Martin; S Aidan Quinn; Ruth Rodriguez-Barrueco; Dennis M Bonal; Elizabeth Charytonowicz; Nataliya Gladoun; Janis de la Iglesia-Vicente; Daniel P Petrylak; Mitchell C Benson; Jose M Silva; Carlos Cordon-Cardo
Journal:  Cancer Cell       Date:  2012-09-11       Impact factor: 31.743

3.  Circulating IGF-1 promotes prostate adenocarcinoma via FOXO3A/BIM signaling in a double-transgenic mouse model.

Authors:  Shuang Wang; Ning Wang; Bin Yu; Mingxing Cao; Yanlong Wang; Yuqi Guo; Yanli Zhang; Ping Zhang; Xiao Yu; Shujing Wang; Li Zeng; Bin Liang; Xin Li; Yingjie Wu
Journal:  Oncogene       Date:  2019-07-16       Impact factor: 9.867

4.  Diagnostic utility of a-methylacyl COA racemase in prostate cancer of the Iranian population.

Authors:  Diana Taheri; Elham Roohani; Mohammad Hossein Izadpanahi; Shahaboddin Dolatkhah; Farshad Aghaaliakbari; Parnaz Daneshpajouhnejad; Mohammad Reza Gharaati; Hamid Mazdak; Shahriar Fesharakizadeh; Yasasmin Beinabadi; Reza Kazemi; Mahtab Rahbar
Journal:  J Res Med Sci       Date:  2021-07-31       Impact factor: 1.852

5.  Guidelines on processing and reporting of prostate biopsies: the 2013 update of the pathology committee of the European Randomized Study of Screening for Prostate Cancer (ERSPC).

Authors:  T Van der Kwast; L Bubendorf; C Mazerolles; M R Raspollini; G J Van Leenders; C-G Pihl; P Kujala
Journal:  Virchows Arch       Date:  2013-08-06       Impact factor: 4.064

Review 6.  Single foci prostate cancer: current diagnosis and management.

Authors:  Ioannis Efthimiou; Konstadinos Skrepetis; Elefteria Bournia
Journal:  Curr Urol       Date:  2013-07-28

Review 7.  [Immunohistochemical algorithms in prostate diagnostics: what's new?].

Authors:  G Kristiansen
Journal:  Pathologe       Date:  2009-12       Impact factor: 1.011

Review 8.  Imaging and Markers as Novel Diagnostic Tools in Detecting Insignificant Prostate Cancer: A Critical Overview.

Authors:  Sergey Reva; Alexander Nosov; Roman Novikov; Sergey Petrov
Journal:  Int Sch Res Notices       Date:  2014-07-15

9.  Prostate adenocarcinoma of secretory type with wide expression of p63 and negativity of the basal marker Ck5/6: Rare subtype of adenocarcinoma of secretory origin and to be differentiated from basal cell carcinoma. Review of literature.

Authors:  Abbas M; Habibian B; Bettendorf O
Journal:  Rare Tumors       Date:  2020-12-01

Review 10.  Molecular markers for prostate cancer in formalin-fixed paraffin-embedded tissues.

Authors:  Tamara Sequeiros; Marta García; Melania Montes; Mireia Oliván; Marina Rigau; Eva Colás; Inés de Torres; Juan Morote; Jaume Reventós; Andreas Doll
Journal:  Biomed Res Int       Date:  2013-11-25       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.